Rotenone

Enterin announces FDA acceptance of an investigator sponsored IND to treat a patient with prodromal multisystem atrophy (MSA) with ENT-01

Retrieved on: 
Wednesday, May 31, 2023
Pure autonomic failure, ATP13A2, Central nervous system, University, PD, Diarrhea, Rotenone, DSM-IV codes, Constipation, CMO, Cell, Life expectancy, Vomiting, Dementia, Oxidative stress, Investigational New Drug, Patient, MSA, Alpha-synuclein, Nausea, Entrepreneurship, Erectile dysfunction, FDA, GI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Disease, Pharmaceutical industry, Dietary supplement, Parkinsonism

Treatment will continue indefinitely or until significant adverse events occur that warrant discontinuation of drug.

Key Points: 
  • Treatment will continue indefinitely or until significant adverse events occur that warrant discontinuation of drug.
  • Individuals diagnosed with MSA have an average life expectancy of 6-8 years and there is no existing treatment which halts the progression of the disease.
  • Phase 3 studies in Parkinson’s disease-related constipation and further Phase 2 studies in Parkinson’s disease-related psychosis and dementia are being planned.
  • On the basis of these symptoms, he has been diagnosed as having prodromal MSA.

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, HGF, Dementia, Athira Pharma, Neurotoxin, Communication, Nature, MET, Doctor of Philosophy, Pain, Neuroprotection, Alpha-synuclein, Brain, Neurotoxicity, Patient, Society, Nerve, Hepatocyte growth factor, Neurodegeneration, Research, Diabetic neuropathy, Security (finance), Peripheral neuropathy, STZ, Rotenone, PD, Lewy body, Oxidative stress, Neuron, Investment, Safety, RATS, Pharmaceutical industry, Aroma compound, Birth control, Neuroscience, L. Athira Krishna

BOTHELL, Wash., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced data highlighting the potential therapeutic benefits of enhancing the HGF/MET neurotrophic system in preclinical models of Parkinson’s disease (PD) and diabetic neuropathy. These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.

Key Points: 
  • These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.
  • The data presented at Neuroscience 2022 show that fosgonimeton (ATH-1017) promotes neuroprotection, reduces alpha-synuclein aggregation in vitro, and improves motor performance in animal models of Parkinsons disease.
  • An oral nanosymposium presentation highlighted the neuroprotective effects of fosgonimeton against neuronal damage and motor deficits in preclinical models of Parkinsons disease.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

The Michael J. Fox Foundation for Parkinson's Research Honors J. Timothy Greenamyre, MD, PhD, with Robert A. Pritzker Prize for Leadership in Parkinson's Research

Retrieved on: 
Tuesday, November 1, 2022
Goal, Awareness, Pritzker family, Mitochondrion, The Michael J. Fox Foundation, Marmon Group, Biomedical sciences, Doctor of Philosophy, Clinical trial, Research, Emory University, MJFF, Parkinson's disease, Family, Neurodegeneration, Disease, Pesticide, Leadership, Pittsburgh Institute of Mortuary Science, Cell, Rotenone, View, Engineering, Government, Illinois Institute of Technology, Volunteering, Neurology, Professor, University, Foundation, PD, Pritzker Architecture Prize, Moshe Sherer, IIT, Genetics, Biomedical Research, Patient, Paraquat, Multimedia, Drug development, Environment, Science, Fox Trial Finder, Pharmaceutical industry, MD, Facebook

This science has and will continue to resonate through the field," said MJFF's Executive Vice President, Research Strategy Todd Sherer, PhD.

Key Points: 
  • This science has and will continue to resonate through the field," said MJFF's Executive Vice President, Research Strategy Todd Sherer, PhD.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research, awarded annually by MJFF since 2011, was established by Karen Pritzker, daughter of Robert A. Pritzker, and her late husband, investor Michael Vlock.
  • "The Robert A. Pritzker Prize for Leadership in Parkinson's Research has recognized, annually, some of the most amazing Parkinson's scientists around the world.
  • The Robert A. Pritzker Prize for Leadership in Parkinson's Research is named in honor of the late Robert A. Pritzker, a renowned industrialist, entrepreneur and philanthropist.

United States Biorational Pesticides Market Outlook 2021-2026: By Crop, Formulation, Source, Mode and State - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Articles, Economy, Business, Biocides, Pesticide, Soil contamination, Business process, Market research, Competition, Marketplace, Organic food, Strategic management

The United States Biorational Pesticides Market is projected to grow with a significant CAGR in the forecast period.

Key Points: 
  • The United States Biorational Pesticides Market is projected to grow with a significant CAGR in the forecast period.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Biorational Pesticides Market.
  • Based on Type, the Biorational Pesticides Market was examined across Biorational Fungicides, Biorational Insecticides, and Biorational Nematicides.
  • What is the market share of the leading vendors in the United States Biorational Pesticides Market?

Statement from the Mi'gmaq Chiefs of New Brunswick - 'Uniting to Save the Salmon'

Retrieved on: 
Friday, August 20, 2021
People, Ecosystem, Fishery, Rotenone, Environmental impact assessment, NB, Fisheries and Oceans Canada, Chief, Community, Communication, Intention, DFO, Bird, Science, Research, Bass, Pacific Ocean, Health, Salmon, Review, Working Group, Food, Environment, Health Canada, Interagency Working Group on Youth Programs, Mammal, Organization, Amphibian, Aquaculture

The health of the salmon is essential to our ecosystem and a significant food source for our People.

Key Points: 
  • The health of the salmon is essential to our ecosystem and a significant food source for our People.
  • In 2019 we discovered smallmouth bass had spread to a small section of the Southwest Miramichi River.
  • Everyone agrees that the overall goal is to save the Atlantic salmon and action needs to be taken.
  • There have been talks between the Chiefs of the Wolastoqey Nation of New Brunswick and the Mi'gmaq to determine how we best to move forward.